L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.
CNX Therapeutics Limited (“CNX Therapeutics”), a leading European specialty pharmaceutical company, has today announced an exclusive partnership with Adalvo to commercialise a prolonged release ...